Keyword: Arena Pharmaceuticals
Arena’s run of positive news continues, with a massive $800 million upfront deal with United for pulmonary arterial hypertension drug ralinepag.
Arena has a new drug candidate heading for clinical trials next year that it says could be a first-in-class option for decompensated heart failure.
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.
Therapix Biosciences' THX-110 reduced Tourette symptoms in adults who had failed other treatments.
Topline data show that Arena's ulcerative colitis candidate, etrasimod, beat out placebo in phase 2.
Arena Pharmaceuticals has posted positive data from a phase 2 trial of its pulmonary arterial hypertension candidate ralinepag.
As Arena continues its struggles with its marketed obesity med Belviq, the company has decided to all but concede defeat that this will not produce major sales--and is now moving its focus more deeply onto its pipeline in the hope that this will yield much-needed long-term revenue.
He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces a culling of 100 U.S. workers and (another) shift in focus.
After a fairly traumatic year, Arena will be looking to ease its own agonies after posting positive Phase I data for its cannabinoid 2 receptor pain drug.